TransMedics Group (NASDAQ:TMDX) Trading Down 5.5% – Should You Sell?

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) traded down 5.5% during mid-day trading on Monday . The company traded as low as $83.77 and last traded at $83.56. Approximately 209,361 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 1,043,676 shares. The stock had previously closed at $88.43.

Analyst Ratings Changes

TMDX has been the subject of several recent research reports. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday. Canaccord Genuity Group restated a “buy” rating and issued a $124.00 price target on shares of TransMedics Group in a research report on Tuesday, June 30th. TD Cowen reaffirmed a “buy” rating and set a $120.00 price objective on shares of TransMedics Group in a research note on Wednesday, July 1st. Stifel Nicolaus upped their price objective on TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, June 18th. Finally, UBS Group cut their target price on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $124.18.

TransMedics Group Stock Performance

The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The stock has a market cap of $2.84 billion, a price-to-earnings ratio of 21.14 and a beta of 1.90. The stock’s fifty day moving average is $79.40 and its 200-day moving average is $92.84.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). The firm had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The company’s revenue for the quarter was up 20.7% on a year-over-year basis. During the same quarter last year, the business posted $0.92 earnings per share. On average, analysts forecast that TransMedics Group, Inc. will post 1.46 EPS for the current year.

Insider Activity at TransMedics Group

In related news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

Several large investors have recently modified their holdings of the business. Harvest Fund Management Co. Ltd bought a new position in shares of TransMedics Group during the 3rd quarter valued at about $29,000. Allworth Financial LP increased its stake in TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares in the last quarter. Parallel Advisors LLC increased its stake in TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after purchasing an additional 83 shares in the last quarter. Ascentis Independent Advisors acquired a new stake in TransMedics Group during the 1st quarter worth approximately $30,000. Finally, North Star Investment Management Corp. acquired a new stake in TransMedics Group during the 1st quarter worth approximately $30,000. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.